These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 34416373)
1. In silico identification of novel inhibitors targeting the DNA-binding domain of the human estrogen receptor alpha. Cao H; Sun Y; Wang L; Pan Y; Li Z; Liang Y J Steroid Biochem Mol Biol; 2021 Oct; 213():105966. PubMed ID: 34416373 [TBL] [Abstract][Full Text] [Related]
3. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α. Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700 [TBL] [Abstract][Full Text] [Related]
4. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy. Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793 [TBL] [Abstract][Full Text] [Related]
5. Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain. Sharma A; Toy W; Guillen VS; Sharma N; Min J; Carlson KE; Mayne CG; Lin S; Sabio M; Greene G; Katzenellenbogen BS; Chandarlapaty S; Katzenellenbogen JA ACS Chem Biol; 2018 Dec; 13(12):3374-3384. PubMed ID: 30404440 [TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor α L543A,L544A mutation changes antagonists to agonists, correlating with the ligand binding domain dimerization associated with DNA binding activity. Arao Y; Hamilton KJ; Coons LA; Korach KS J Biol Chem; 2013 Jul; 288(29):21105-21116. PubMed ID: 23733188 [TBL] [Abstract][Full Text] [Related]
7. Determination and analysis of agonist and antagonist potential of naturally occurring flavonoids for estrogen receptor (ERα) by various parameters and molecular modelling approach. Puranik NV; Srivastava P; Bhatt G; John Mary DJS; Limaye AM; Sivaraman J Sci Rep; 2019 May; 9(1):7450. PubMed ID: 31092862 [TBL] [Abstract][Full Text] [Related]
8. Design and Synthesis of Novel Breast Cancer Therapeutic Drug Candidates Based upon the Hydrophobic Feedback Approach of Antiestrogens. Ohta K; Kaise A; Taguchi F; Aoto S; Ogawa T; Endo Y Molecules; 2019 Nov; 24(21):. PubMed ID: 31683895 [TBL] [Abstract][Full Text] [Related]
9. 1,2,4-Triazine Sulfonamides: Synthesis by Sulfenamide Intermediates, In Vitro Anticancer Screening, Structural Characterization, and Molecular Docking Study. Branowska D; Karczmarzyk Z; Wolińska E; Wysocki W; Morawiak M; Urbańczyk-Lipkowska Z; Bielawska A; Bielawski K Molecules; 2020 May; 25(10):. PubMed ID: 32429377 [TBL] [Abstract][Full Text] [Related]
10. Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists. Lloyd DG; Smith HM; O'Sullivan T; Knox AS; Zisterer DM; Meegan MJ Med Chem; 2006 Mar; 2(2):147-68. PubMed ID: 16787364 [TBL] [Abstract][Full Text] [Related]
11. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy. Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842 [TBL] [Abstract][Full Text] [Related]
12. Anacardic acid inhibits estrogen receptor alpha-DNA binding and reduces target gene transcription and breast cancer cell proliferation. Schultz DJ; Wickramasinghe NS; Ivanova MM; Isaacs SM; Dougherty SM; Imbert-Fernandez Y; Cunningham AR; Chen C; Klinge CM Mol Cancer Ther; 2010 Mar; 9(3):594-605. PubMed ID: 20197399 [TBL] [Abstract][Full Text] [Related]
13. In silico Molecular Modelling of Selected Natural Ligands and their Binding Features with Estrogen Receptor Alpha. Maruthanila VL; Elancheran R; Roy NK; Bhattacharya A; Kunnumakkara AB; Kabilan S; Kotoky J Curr Comput Aided Drug Des; 2019; 15(1):89-96. PubMed ID: 30306879 [TBL] [Abstract][Full Text] [Related]
14. Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer. Zhang X; Wang Y; Li X; Wu J; Zhao L; Li W; Liu J J Med Chem; 2021 Jun; 64(11):7575-7595. PubMed ID: 34056898 [TBL] [Abstract][Full Text] [Related]
15. Phenytoin is an estrogen receptor α-selective modulator that interacts with helix 12. Fadiel A; Song J; Tivon D; Hamza A; Cardozo T; Naftolin F Reprod Sci; 2015 Feb; 22(2):146-55. PubMed ID: 25258361 [TBL] [Abstract][Full Text] [Related]
16. Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha. Chakraborty S; Biswas PK J Mol Model; 2014 Aug; 20(8):2338. PubMed ID: 25060147 [TBL] [Abstract][Full Text] [Related]
17. Structural insight into the antagonistic action of diarylheptanoid on human estrogen receptor alpha. Geetha Rani Y; Lakshmi BS J Biomol Struct Dyn; 2019 Mar; 37(5):1189-1203. PubMed ID: 29557271 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents. Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819 [TBL] [Abstract][Full Text] [Related]
19. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells. Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451 [TBL] [Abstract][Full Text] [Related]
20. Elucidating Binding Sites and Affinities of ERα Agonists and Antagonists to Human Alpha-Fetoprotein by In Silico Modeling and Point Mutagenesis. Moldogazieva NT; Ostroverkhova DS; Kuzmich NN; Kadochnikov VV; Terentiev AA; Porozov YB Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]